| Keywords: |
cancer survival; protein expression; treatment outcome; vascular endothelial growth factor a; overall survival; prednisone; clinical trial; angiogenesis inhibitor; bevacizumab; doxorubicin; cancer combination chemotherapy; drug safety; hypertension; unspecified side effect; drug approval; note; disease free survival; rituximab; outcome assessment; follow up; colorectal cancer; vasculotropin receptor; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; food and drug administration; risk assessment; risk; b cell lymphoma; lymphoma, b-cell; cancer regression; cytokines; antibodies, monoclonal; correlation analysis; vein thrombosis; vasculotropin a; lactate dehydrogenase; metastasis potential; angiogenesis inhibitors; tumor vascularization; digestive system perforation; wound healing impairment; artery thrombosis; lymphoma, large-cell, diffuse
|
